BCL2L1 and melanoma: To determine whether the findings above are relevant to the current treatment of melanoma, we evaluated the efficacy of MCL1 plus BCLXL inhibition in a panel of patient derived lines with diverse genetic backgrounds established from several subtypes of melanomas (Supplementary Table 1), with the same conditions as in Fig. 1c and Supplementary Fig. 1.